Welcome to our dedicated page for CMNDF news (Ticker: CMNDF), a resource for investors and traders seeking the latest updates and insights on CMNDF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CMNDF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CMNDF's position in the market.
Clearmind Medicine Inc. (CMNDF) announced a public offering of 1,153,847 common shares at US$6.50 each, aiming for gross proceeds of US$7.5 million. This follows a 1-for-30 reverse stock split effective September 30, 2022. Aegis Capital Corp. has an option for an additional 173,077 shares, potentially bringing total proceeds to US$8.6 million. Trading under the ticker 'CMND' on the Nasdaq begins on November 15, 2022. The offering closes around November 17, 2022, subject to conditions. Securities sold are restricted from trading in Canada until March 17, 2023.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) is featured on 'Psychedelics Tonight', a show highlighting the benefits of psychedelic medicines. The latest episode, 'Psychedelic Novelty - Before it was Cool', showcases Clearmind's proprietary molecule MEAI, which has potential applications in treating alcohol use disorder. The episode is available on ALTRD.TV and will be followed by another airing on October 17. Clearmind aims to develop novel psychedelic-derived therapeutics targeting significant health issues with a robust intellectual property portfolio of seven patent families.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) announced a share consolidation effective September 30, 2022, reducing 39,592,344 outstanding shares to approximately 1,319,744 shares. This consolidation will take place at a ratio of 1 post-consolidation share for every 30 pre-consolidation shares. Trading on a post-consolidation basis will begin on October 3, 2022. Adjustments will also be made to stock options and share purchase warrants. The company focuses on developing psychedelic-derived therapeutics for health issues such as alcohol use disorder.
Clearmind Medicine Inc. (CSE: CMND; OTC Pink: CMNDF) has filed a provisional patent application for therapies targeting metabolic syndromes, including obesity. This application is a result of the company's collaboration with SciSparc Ltd. and the Hebrew University of Jerusalem. The innovative patent focuses on combining Clearmind's MEAI, a psychedelic treatment for addictions, with SciSparc's CannAmide™, an obesity treatment. CEO Dr. Adi Zuloff-Shani emphasized the urgent need for effective anti-obesity treatments, citing MEAI's potential based on pre-clinical studies.
Clearmind Medicine Inc. (OTC Pink: CMNDF) announced it will issue 122,160 common shares valued at $10,000 monthly starting May 1, 2022, to consultants. This issuance is part of their strategy to compensate services while adhering to applicable securities laws. Clearmind focuses on developing psychedelic-derived therapeutics for underaddressed health issues, particularly alcohol use disorder, and currently holds four patent families for its compounds. The company aims to expand its intellectual property portfolio.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) announced promising pre-clinical results for its novel psychedelic compound MEAI as a treatment for cocaine addiction. The study, led by Professor Gal Yadid, showed that 60% of the animals in the trial exhibited a significant decrease in cocaine cravings after receiving MEAI. This finding aligns with previous research, underscoring MEAI's potential as a dedicated treatment for cocaine addiction. The company aims to address the pressing need for effective addiction therapies, highlighting MEAI's commercial potential.
Clearmind Medicine has appointed Dr. John H. Krystal, a leading expert in alcoholism and depression, to its Scientific Advisory Board. Dr. Krystal is well-known for his research linking neurobiology and treatment of mental health disorders. Clearmind focuses on developing psychedelic-derived therapeutics to address untreated health issues. The company holds patents for the non-hallucinogenic compound MEAI and is collaborating with Hebrew University and Bar Ilan University to expand its R&D capabilities.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) announced the appointment of Mr. Alan Rootenberg as Chief Financial Officer, effective June 14, 2022. The company expressed gratitude to the outgoing CFO, Mr. Oded Gilboa, who also resigned from the Board of Directors. Clearmind focuses on developing psychedelic-derived therapeutics for alcohol use disorder and holds patents for the non-hallucinogenic compound MEAI. The company collaborates with the Hebrew University of Jerusalem and Bar Ilan University to expand R&D capabilities.
Clearmind Medicine has announced positive pre-clinical results for its novel psychedelic molecule, MEAI, aimed at treating cocaine addiction. Conducted by Bar Ilan University, the study revealed that rats given MEAI spent less time in areas associated with cocaine, indicating its potential to reduce cravings. The 5 mg/kg dosage was notably effective. Clearmind has filed a provisional patent related to this treatment, marking a significant step in addressing cocaine addiction, a rising global crisis.
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) has filed a provisional patent application for a novel treatment for cocaine addiction, in collaboration with SciSparc Ltd. The proposed combination of Clearmind's MEAI and SciSparc's CannAmide™ aims to serve as an anti-reward agent for cocaine addiction. Cocaine addiction remains a significant health crisis in the U.S., affecting over 1.3 million people and contributing to thousands of overdose deaths annually. This initiative positions Clearmind to address a gap in treatment options for substance abuse disorders.
FAQ
What is the market cap of CMNDF (CMNDF)?
